Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Receptors on B and T cells hint at what the immune system is targeting. An AI approach called Mal-ID developed increases diagnostic accuracy, particularly for autoimmune diseases.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Although customization is a popular initiative among the competition, AB is already one of the largest providers of custom target-date funds in the US, and its capabilities in managing and ...

Companies that have increased their book values and have low Price to Earnings Ratio ...